Key result
Heparin and low-molecular weight heparins exert diverse polypharmacological effects, including anti-inflammatory and anti-adhesive properties, explaining their clinical impact beyond thrombosis.
Heparin and LMWH have diverse polypharmacological effects beyond simple anticoagulation, impacting inflammation and cancer cell interactions.
Answers are grounded in this paper and cite their sources.
May inform heparin use in inflammation; leaves open prospective trials to confirm non-antithrombotic benefits.
Heparin and its improved version, low-molecular weight heparin (LMWH), are known to exert polypharmacological effects at various levels. Early studies focused on the plasma anti-Xa and anti-IIa pharmacodynamics of different LMWHs. Other important pharmacodynamic parameters for heparin and LMWH, including effects on vascular tissue factor pathway inhibitor (TFPI) release, inhibition of inflammation through NFkappaB, inhibition of key matrix-degrading enzymes, selectin modulation, inhibition of platelet-cancer cell interactions, and inflammatory cell adhesion, help explain the diverse clinical impact of this class of agents in thrombosis and beyond.
No takes yet. Share an insight, caveat, or question.
Shaker A. Mousa (2010) conducted a review in Thrombosis. Heparin and Low-Molecular Weight Heparins (LMWH) was evaluated. Heparin and low-molecular weight heparins exert diverse polypharmacological effects, including anti-inflammatory and anti-adhesive properties, explaining their clinical impact beyond thrombosis.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: